Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF)
OTCMKTS · Delayed Price · Currency is USD
2.610
-0.045 (-1.69%)
At close: Feb 6, 2026
Shanghai Fosun Pharmaceutical (Group) Employees
Shanghai Fosun Pharmaceutical (Group) had 40,234 employees as of June 30, 2025. The number of employees decreased by 323 or -0.80% since the number was reported on December 31, 2024.
Employees
40,234
Change
-323
Growth
-0.80%
Revenue / Employee
$136,973
Profits / Employee
$11,369
Market Cap
9.73B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 40,234 | -323 | -0.80% |
| Dec 31, 2024 | 40,557 | 187 | 0.46% |
| Dec 31, 2023 | 40,370 | 1,971 | 5.13% |
| Dec 31, 2022 | 38,399 | 2,120 | 5.84% |
| Dec 31, 2021 | 36,279 | 4,021 | 12.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jushi Holdings | 1,234 |
| MariMed | 832 |
| Glass House Brands | 374 |
| Earth Science Tech | 76 |
| Elite Pharmaceuticals | 68 |
| Radnostix | 42 |
| Healthy Extracts | 2 |
Shanghai Fosun Pharmaceutical (Group) News
- 20 days ago - China’s Fosun Pharma eyes spin-off listing of vaccine unit in hot Hong Kong IPO market - South China Morning Post
- 4 months ago - China’s ‘health silk road’ in Africa gets a boost with insulin, pharma projects - South China Morning Post
- 5 months ago - Fosun’s Henlius in talks with Johnson & Johnson, Roche on cancer drug - South China Morning Post
- 11 months ago - Shanghai Fosun Pharmaceutical reports FY results - Seeking Alpha
- 2 years ago - Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse - Reuters
- 3 years ago - Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech - Forbes
- 4 years ago - Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal - Seeking Alpha
- 5 years ago - Pandemic Accelerates China's Drive Into mRNA Treatments - Seeking Alpha